GlassScriptPhysician profile
Lily Xu
NPI 1225458623
$3,842.67
in general payments reported to CMS, 2019-2025
26 companies · $454 in 2025
The $454 reported for 2025 was more than what 82% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $875 · 2020: $621 · 2021: $850 · 2022: $175 · 2023: $425 · 2024: $444 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,322.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $527.62 | 2019-2025 | Verquvo, Belsomra, Capvaxive |
| Abbvie INC. | $471.67 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $388.98 | 2019-2024 | |
| Exact Sciences Corporation | $357.99 | 2023-2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $296.23 | 2019-2024 | |
| Novo Nordisk INC | $247.06 | 2019-2025 | |
| Amarin Pharma, INC. | $228.72 | 2019-2022 | |
| Amgen INC. | $176.63 | 2019-2023 | Prolia, Evenity |
| Janssen Pharmaceuticals, INC | $149.76 | 2019-2022 | |
| Esperion Therapeutics, INC. | $148.81 | 2021 | |
| Lilly USA, LLC | $139.34 | 2019-2023 | Jardiance |
| Glaxosmithkline, LLC. | $131.47 | 2019-2024 | Trelegy Ellipta |
| Hologic Sales and Service, LLC | $125.00 | 2019 | |
| Boston Scientific Corporation | $116.38 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $77.14 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $38.10 | 2020 | |
| Ironwood Pharmaceuticals, INC | $36.61 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $33.34 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $24.29 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $20.69 | 2025 | Rexulti |
| Shield Therapeutics INC | $20.63 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $19.59 | 2019 | |
| Shire North American Group INC | $17.95 | 2019 | |
| Allergan, INC. | $16.75 | 2019 | |
| Sanofi Pasteur INC. | $16.19 | 2020 | |
| Ibsa Pharma INC. | $15.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lily Xu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.